Parkinson’s

Alpha-synuclein protein aggregate
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #Phase II trial

Immunotherapy for Parkinson’s induces positive responses

AC Immune has announced additional interim safety and positive immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056, its anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease (PD).  Dr Andrea Pfeifer, CEO of AC Immune, commented: “We continue to be encouraged by the data… Read More

#News

Genetic engineering concept
#AskBio #FDA #Gene therapy #Neuroscience #Parkinson's

Further FDA support for Parkinson’s gene therapy

AskBio’s investigational gene therapy AB-1005 for the treatment of Parkinson’s disease (PD) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA).  The FDA decision follows a review of information and data provided by AskBio, including clinical evidence from the open label Phase… Read More

#News #Regulatory

Degeneration of dopaminergic neuron in Parkinson's disease
#BioArctic #Monoclonal antibodies #Neuroscience #Parkinson's #Phase II trial

Clinical trial will test monoclonal antibody in Parkinson’s disease

BioArctic says it has dosed the first patient with exidavnemab in the EXIST Phase IIa study in Parkinson’s disease patients.   Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders… Read More

#News

#Events #Gain Therapeutics #Neuroscience 2024 #Parkinson's #Society for Neuroscience

Vodcast: Joanne Taylor, Gain Therapeutics, at Neuroscience 2024

At the Society for Neuroscience’s annual meeting, Neuroscience 2024, which took place in October 2024 in Chicago, DDW’s Megan Thomas met with Joanne Taylor, Senior Vice President of Research at Gain Therapeutics. Read More

#Videos

#Dementia #Funding #Investment #Parkinson's #UK Dementia Research Institute

£20m funding offered to advance breakthroughs in dementia research

The UK Dementia Research Institute has received major new government funding to boost translational research into dementia and related neurodegenerative conditions such as Parkinson’s and motor neuron disease. The UK-wide research institute will receive an initial £20 ($25.9) million from the National Institute for Health and… Read More

#News

Mitochondria
#Mitochondria #Neuroscience #NRG Therapeutics #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Novel Parkinson’s therapy protects mitochondrial function

NRG Therapeutics has been awarded a $5 million grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease. The company says NRG5051 also has potential in other neurological diseases such as amyotrophic lateral sclerosis (ALS). Read More

#Business & Investment #Editor's Choice #News

Degeneration of dopaminergic neuron in Parkinson's disease
#Collaboration #Parkinson's #SandboxAQ #The Michael J Fox Foundation for Parkinson’s Research (MJFF) #University of Dundee

Partners launch $25m initiative to develop Parkinson’s treatments

SandboxAQ is collaborating with the University of Dundee in the UK to improve its inhibitor for the gene most commonly associated with Parkinson's disease (PD). The company has signed a $25 million research grant through The Michael J Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) programme. Read More

#Business & Investment #News

Neuroscience Parkinson's disease
#Mitsubishi Tanabe Pharma America #Neurodegenerative disorders #NeuroDerm #Parkinson's #Phase III trial

Data support one-year efficacy of ND0612 in Parkinson’s disease

New data from the Phase III BouNDless trial and its ongoing open-label extension (OLE) support the long-term efficacy of ND0612 in people with Parkinson’s disease (PD) experiencing motor fluctuations. The new clinical trial data was shared at the 2024 International Congress of Parkinson’s Disease and Movement… Read More

#News

World Parkinson's Day
#Charity #Funding #Neurodegenerative disorders #Neuroscience #Parkinson's

Parkinson’s researchers receive nearly $3 million in grant funding

The US Parkinson’s Foundation has invested nearly $3 million for 33 grants to accelerate Parkinson’s disease (PD) research. The research grants will fund scientists conducting studies across various aspects of PD to bring forward new therapies, treatments, and ultimately a cure for the disease. Read More

#News

Neurons in the brain
#Centogene #Drug targets #Genetics #Neuroscience #Parkinson's

15% of Parkinson’s cases linked to genetic factors, study says 

Centogene has announced data from its Rostock International Parkinson’s Disease (ROPAD) Study revealing the genetic factors and prevalence of Parkinson’s disease (PD).   The findings from the study indicate that approximately 15% of PD-related cases are tied to genetic variants, with the majority being linked to LRRK2 and… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

New DDW Highlights podcast: 29 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy,… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

This week in drug discovery (22-26 July) 

News round-up for 22-26 July by DDW Senior Digital Content Editor Diana Spencer. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing… Read More

#News

Human brain
#Funding #Lario Therapeutics #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Lario Therapeutics awarded $6m for Parkinson’s drug research

Biopharmaceutical company Lario Therapeutics has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to fund Lario’s preclinical programme investigating selective CaV2.3 calcium channel inhibition as a novel and disease-modifying approach for treatment of… Read More

#News

Gene therapy
#Asklepios BioPharmaceutical #FDA #Gene therapy #MHRA #Neurodegenerative disorders #Parkinson's

US and UK fast track designations for Parkinson’s gene therapy

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment… Read More

#News #Regulatory

#Funding #Mission Therapeutics #Neurodegenerative disorders #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Mission awarded $5.2m for disease-modifying Parkinson’s treatment

Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK. The funding will help advance Mission’s potential disease-modifying treatment for Parkinson’s disease (PD), MTX325. MTX325 is a potent, selective, small molecule brain-penetrant USP30 inhibitor, which is designed to protect dopamine-producing… Read More

#Business & Investment #Editor's Choice #News